CFSE Cell Division Tracker Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester Kit, CFDA SE Kit
CFSE_Cell_Tracking_Kit_022014
Human peripheral blood mononuclear cells were stained with CFSE Cell Division Tracking Kit, and then stimulated with (filled histogram) or without (open histogram) PHA for 5 days. On day 5, cells were harvested and the CFSE fluorescent staining was analyzed by flow cytometry.
  • CFSE_Cell_Tracking_Kit_022014
    Human peripheral blood mononuclear cells were stained with CFSE Cell Division Tracking Kit, and then stimulated with (filled histogram) or without (open histogram) PHA for 5 days. On day 5, cells were harvested and the CFSE fluorescent staining was analyzed by flow cytometry.
Cat # Size Price Quantity Check Availability
423801 1 kit $101.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CFSE Cell Division Tracker Kit is composed of 5 vials, 100 µg per vial of CFSE (formally known as 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester of CFDA SE), and 500 µl of anhydrous DMSO. CFSE is able to passively diffuse into cells. Inside the cell, its acetate groups are cleaved by intracellular esterases, and the molecules are converted to fluorescent esters. CFSE is retained within the cell and covalently couples to intracellular molecules via its succinimidyl group. Due to this covalent coupling reaction, fluorescent CFSE can be retained within the cell for an extremely long period. Also, due to this stable linkage, once the dye has been incorporated within the cell, it is not transferred to adjacent cells. CFSE is widely used for cell proliferation assays and in vivo cell tracking.

Technical data sheet

Product Details

Preparation
The CFSE Cell Division Tracker Kit is composed of lyophilized CFSE and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 36 µl of DMSO to one vial of CFSE dye until fully dissolved.
Storage & Handling
Store CFSE Cell Division Tracker Kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the CFSE, use immediately, or store at -20°C in a dry place and protected from light, preferably in a dessicator or in a container with desiccant for no more than one month.
Application

ICFC - Quality tested
In vivo cell tracking1 - Reported in the literature, not verified in house

Recommended Usage

This lot has been tested by flow cytometric analysis of in vitro cell proliferation assay. It can be used at concentrations ranging from 0.5 - 10 µM for cell labeling. It is recommended that the reagent be titrated for optimal performance for each cell type, culturing condition, or application.

Application Notes

The molecular weight of CFSE is 557.47. The excitation and emission wavelengths of CFSE-labeled cells are 492 nm and 517 nm, respectively. Each 100 µg vial of CFSE may be reconstituted with 36 µl of anhydrous DMSO to yield a stock concentration of 5 mM.

Materials Provided:
5 vials x 100 µg CFSE
500 µl anhydrous DMSO

CFSE Labeling Procedure: 
1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
2. Prepare stock solution by reconstituting 1 vial of lyophilized CFSE dye in 36 µL of DMSO to make a 5 mM solution.
3. Prepare a 5 µM working solution by diluting 1 µL of 5 mM CFSE stock solution in 1 mL PBS for every 1 mL of cell suspension (or at an optimal working concentration as determined by titration).
4. Spin down and resuspend cells at 10-100 x 106 cells/mL in the CFSE working solution.
5. Incubate cells for 20 minutes at room temperature or 37°C and keep protected from light.
6. Quench the staining by adding 5 times the original staining volume of cell culture medium containing 10% FBS.
7. Pellet cells and resuspend in pre-warmed cell culture medium. 
8. Incubate cells for 10 minutes.
9. After incubation, CFSE labeled cells are ready for downstream applications or analysis.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.


Watch a Scientific Poster video of this product.

Application References

(PubMed link indicates BioLegend citation)
  1. Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9.
  2. Miller MJ, et al. 2002. Science 296:1869.
  3. Tai LH, 2013. Clin Cancer Res. 19:5104. PubMed
  4. Svajger U, et al. 2014. J Lukoc Biol. 95:33. PubMed
Product Citations
  1. Boland LK, et al. 2019. Front Immunol. 10:1080. PubMed
  2. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  3. Nalbandian M, et al. 2022. Life Sci Alliance. 5: . PubMed
  4. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  5. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  6. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  7. Tang M, et al. 2022. Biomolecules. 12: . PubMed
  8. Zhang Z, et al. 2023. J Transl Med. 21:23. PubMed
  9. Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed
  10. Garcia-Becerra N, et al. 2023. Cancers (Basel). 15: . PubMed
  11. Lin CP, et al. 2023. EMBO J. 42:e111614. PubMed
  12. Wang R, et al. 2023. iScience. 26:105954. PubMed
  13. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  14. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  15. Li Y, et al. 2022. Transl Oncol. 21:101424. PubMed
  16. Mews EA, et al. 2022. ACS Nano. 16:12185. PubMed
  17. Shen M, et al. 2022. Adv Sci (Weinh). 9:e2203523. PubMed
  18. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  19. Nasiri F, et al. 2023. Front Immunol. 14:1063838. PubMed
  20. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  21. Bayat H, et al. 2023. Mol Ther Nucleic Acids. 32:432. PubMed
  22. Wu C, et al. 2023. Cancer Metab. 11:7. PubMed
  23. Romo ML, et al. 2023. PLoS Negl Trop Dis. 17:e0011386. PubMed
  24. Wang Z, et al. 2023. Mediators Inflamm. 2023:9810733. PubMed
  25. Labadie KP, et al. 2023. Cancer Gene Ther. . PubMed
  26. Ennis S, et al. 2023. iScience. 26:106943. PubMed
  27. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  28. Page N, et al. 2018. Immunity. 48:937. PubMed
  29. Zupancic E, et al. 2017. Journal of Controlled Release. 10.1016/j.jconrel.2017.05.014. PubMed
  30. Boyt DT, et al. 2020. J R Soc Interface. 17:20190815. PubMed
  31. Wen Y, et al. 2020. J Invest Dermatol. . PubMed
  32. Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed
  33. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  34. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  35. Hui CW, et al. 2022. Front Immunol. 13:919854. PubMed
  36. Nguyen DT, et al. 2022. Cells. 11:. PubMed
  37. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  38. Chen X, et al. 2021. Cell Death Differ. 28:1237. PubMed
  39. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  40. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  41. Saito S, et al. 2020. Nutrients. 12:. PubMed
  42. Deng H, et al. 2021. J Asthma Allergy. 14:839. PubMed
  43. Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed
  44. Just S, et al. 2016. Sci Rep. 6:39796. PubMed
  45. Onodera T, et al. 2015. Sci Rep. 5:16801. PubMed
  46. Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
  47. Guo HZ, et al. 2021. Sci Adv. 7:eabg4167. PubMed
  48. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  49. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  50. Moser B, et al. 2021. Mol Cancer. 20:16. PubMed
  51. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  52. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  53. Sertori R, et al. 2022. Front Immunol. 13:928252. PubMed
  54. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  55. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  56. Lv M, et al. 2020. Cell Res. 30:966. PubMed
  57. Codo AC, et al. 2020. Cell Metab. 32:437. PubMed
  58. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  59. Lu Z, et al. 2022. Nat Commun. 13:6623. PubMed
  60. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  61. Di Buduo CA, et al. 2021. eLife. 10:00. PubMed
  62. Yang Q, et al. 2020. Theranostics. 6.2375. PubMed
  63. Krueger CC, et al. 2019. Front Immunol. 10:1831. PubMed
  64. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  65. Monteran L, et al. 2022. Nat Commun. 13:5797. PubMed
  66. Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. Wei C, et al. 2016. Cell Death Dis. 7:e2489. PubMed
  68. Shifrut E et al. 2018. Cell. 175(7):1958-1971 . PubMed
  69. Rodriguez RM, et al. 2019. Cell Rep. 29:860. PubMed
  70. Luo Q, et al. 2020. Cancer Sci. 111:4000. PubMed
  71. Tian M, et al. 2021. Elife. 10:. PubMed
  72. Kanemaru H, et al. 2021. iScience. 24:103067. PubMed
  73. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  74. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  75. Kwiecinski JM, et al. 2021. Cell Rep. 36:109462. PubMed
  76. Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed
  77. Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed
  78. Beghelli D, et al. 2017. Oxid Med Cell Longev. 10.1155/2017/7468064. PubMed
  79. Mercer F, et al. 2016. PLoS Negl Trop Dis. 10: 0004913. PubMed
  80. Burand AJ, et al. 2020. Front Immunol. 11:143. PubMed
  81. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  82. Kwee BJ, et al. 2019. Sci Adv. 5:eaav6313. PubMed
  83. Wettersten HI, et al. 2019. Cancer Res. 79:5048. PubMed
  84. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  85. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  86. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  87. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  88. Chang T, et al. 2020. Aging (Albany NY). 12:21147. PubMed
  89. Lim J, et al. 2020. Sci Adv. 6:eaba1334. PubMed
  90. Chen W, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2028. PubMed
  91. Montel‐Hagen A et al. 2019. Cell stem cell. 24(3):376-389 . PubMed
  92. Soloff A, et al. 2017. J Appl Toxicol. 10.1002/jat.3465. PubMed
  93. Sen S, et al. 2018. J Immunol. 201:440. PubMed
  94. Sung J, et al. 2015. J Infect Dis. 212: 258 - 263. PubMed
  95. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  96. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  97. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  98. Georgouli M et al. 2019. Cell. 176(4):757-774 . PubMed
  99. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  100. Barsheshet Y, et al. 2017. Proc Natl Acad Sci U S A. 114:6086. PubMed
  101. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  102. Ward D, et al. 2016. Haematologica. 101: 286 - 296. PubMed
  103. Lhuillier C, et al. 2021. J Clin Invest. 131:. PubMed
  104. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  105. Kwantwi LB, et al. 2021. Bioengineered. 12:6996. PubMed
  106. Cao M, et al. 2021. Int J Cancer. 149:460. PubMed
  107. Bonaccorsi-Riani E, et al. 2015. PLoS One. 10: 0136106. PubMed
  108. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed

Antigen Details

Biology Area
Cell Biology, Cell Proliferation and Viability, Neuroscience
Antigen References

1. Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9.
2. Lyons AB, 2000. J. Immunol. Methods 243:147.

Gene ID
NA
Go To Top Version: 5    Revision Date: 05/20/2020

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login/Register
Forgot your password? Reset Password
Request an Account